American Healthcare REIT (AHR) Q4 2023: Trilogy NOI Margin Climbs to 16.7% as Senior Housing Outpaces Medical Office
American Healthcare REIT’s first quarter as a public REIT spotlighted a decisive shift toward operationally intensive senior housing, with Trilogy’s NOI margin reaching 16.7% and SHOP growing 44.9% YoY. Balance sheet de-risking via the $773 million IPO and aggressive debt paydown positions AHR for measured growth, but management signaled a more conservative stance on outpatient medical and triple net segments. With operator transitions largely complete and embedded growth levers in place, AHR’s near-term trajectory will hinge on senior housing execution and prudent capital allocation.
Summary
- Senior Housing Margin Expansion: Trilogy and SHOP segments drove substantial NOI and occupancy gains, reinforcing portfolio tilt.
- Balance Sheet Reset: IPO proceeds enabled rapid deleveraging, lowering floating-rate debt exposure and interest burden.
- Growth Levers Centered on Trilogy: Embedded options and operator transitions set stage for continued earnings accretion.
Business Overview
American Healthcare REIT (AHR) is a diversified healthcare real estate investment trust (REIT) focused on senior housing, skilled nursing, outpatient medical, and triple net leased assets. The company’s core business model blends RIDEA operating structures—where AHR participates in property operations—and traditional net lease arrangements. As of Q4 2023, the largest contributor to net operating income (NOI) is the Trilogy integrated senior health campus platform, representing about 49% of total NOI, followed by outpatient medical buildings (27%), triple net leased assets (13%), and the SHOP (Senior Housing Operating Portfolio) segment (9%).
Performance Analysis
Q4 2023 marked a transformative period for AHR, with the company’s RIDEA operating portfolio, especially the Trilogy assets, driving both occupancy and NOI margin improvements. Same-store NOI for the quarter grew 9.5% year-over-year, with Trilogy’s same-store NOI up 14% for the year and its NOI margin expanding to 16.7%. SHOP segment performance was even more pronounced, posting 44.9% NOI growth in Q4 and 27.2% for the full year, as occupancy rose 415 basis points YoY. These gains were attributed to both robust demand fundamentals and proactive operator transitions.
Outpatient medical buildings delivered more modest growth, with 3.2% same-store NOI increase for 2023, but management cautioned that sustaining this growth will be challenging due to known vacancies and broader health system consolidation. Triple net leased assets provided stable, though lower, growth at 2%. The company’s $773 million IPO enabled the retirement of $721 million in high-cost, floating-rate debt, materially reducing interest expense and improving leverage metrics. Management projects net debt to annualized adjusted EBITDA in the low six times range post-transaction.
- Senior Housing Outperformance: Both Trilogy and SHOP segments posted above-industry occupancy and margin growth, highlighting operational leverage.
- Expense Controls Materialize: Agency labor costs in SHOP fell by nearly 70% from 2022 peaks, supporting margin expansion.
- Medical Office Headwinds: Anticipated occupancy declines and re-leasing downtime signal a near-term NOI drag in outpatient medical.
AHR’s portfolio is increasingly anchored in high-acuity, needs-based care, with management signaling further concentration in senior housing and selective divestiture of lower-growth medical office assets.
Executive Commentary
"We are proud to be part of the listed REIT community and are as optimistic as ever about the prospects for our business... Our Trilogy assets comprise the largest part of our business and are unique among listed healthcare REITs."
Danny Prosky, President and CEO
"We raised nearly $773 million and utilized the net proceeds to pay down $721 million of shorter term and floating rate indebtedness... which will result in significant interest expense savings going forward and a large reduction in floating rate debt outstanding."
Brian Pei, Chief Financial Officer
Strategic Positioning
1. RIDEA Platform and Trilogy Growth Option
AHR’s RIDEA structure, where the REIT shares in operations and upside, is central to its growth thesis. The Trilogy joint venture, now 75% owned, is fully consolidated and offers a purchase option for the remaining interest through September 2025. Management views this as a “tremendous growth opportunity with limited operating risk,” positioning Trilogy as AHR’s primary earnings growth lever.
2. Senior Housing Operating Portfolio Upside
SHOP assets are poised for continued outsized NOI growth as operator transitions and asset management strategies mature. Management expects to capture further occupancy and rate gains, with SHOP projected to grow 25-30% in 2024, capitalizing on demographic tailwinds and limited new supply.
3. Outpatient Medical and Triple Net De-emphasis
Outpatient medical and triple net leased segments are being deprioritized, with medical office now 27% of NOI (down from 35% recently) and targeted for selective asset sales. Management noted that growth in these segments will lag the senior housing portfolio, and future acquisitions will be highly selective due to lower risk-adjusted returns.
4. Capital Allocation and Leverage Discipline
Post-IPO, AHR is focused on maintaining conservative leverage, with proceeds earmarked for debt reduction and only measured external growth. The company will pursue asset sales (notably $68 million in medical office dispositions) to further improve leverage, and will only consider accretive, low-risk development or acquisition opportunities.
5. Operator Transition and Asset Management
Operator transitions in SHOP are now complete, and AHR is leveraging proven partners to drive performance. The company cites a recent example in Texas, where a management change led to a 900 basis point occupancy gain in less than a year, illustrating the impact of active asset management.
Key Considerations
This quarter’s results reflect a deliberate pivot toward operationally intensive, higher-growth senior housing, underpinned by Trilogy’s scalable platform and SHOP’s ongoing recovery. Management’s transparent discussion of capital allocation, operator transitions, and segment-level growth signals a clear strategic focus for 2024.
Key Considerations:
- Trilogy Purchase Option Timing: The option to acquire the remaining Trilogy JV interest is highly accretive, but timing will balance leverage discipline against incremental value creation.
- SHOP and Trilogy Margin Trajectory: Margin expansion is expected to continue as occupancy and rates rise, but management is not embedding aggressive assumptions in guidance.
- Medical Office Leasing Risk: Known vacancies and health system consolidation will pressure outpatient medical NOI in the near term, with recovery dependent on re-leasing success.
- Dispositions and Capital Recycling: Asset sales are focused on medical office, with proceeds directed to debt reduction rather than new acquisitions.
Risks
Key risks include operational complexity in the RIDEA structure, especially in Trilogy and SHOP, where execution on occupancy, rates, and expense controls directly impacts earnings. Outpatient medical faces occupancy and re-leasing risk amid industry consolidation. Regulatory or reimbursement changes, particularly in skilled nursing, could introduce “stroke of the pen” risk. Dividend coverage remains tight for 2024, though management is confident in 2025 recovery.
Forward Outlook
For Q1 2024, AHR expects:
- Continued occupancy and NOI growth in Trilogy and SHOP segments.
- Outpatient medical NOI to be flat to slightly down due to known vacancies.
For full-year 2024, management issued guidance for normalized funds from operations (FFO) of $1.18 to $1.24 per share, with:
- 5-7% total portfolio same-store NOI growth.
- Integrated senior health campus NOI up 8-10%, SHOP up 25-30%, outpatient medical flat or slightly down, triple net up 1-3%.
Management emphasized that guidance does not include the impact of exercising Trilogy purchase options or additional acquisitions, and that leverage and balance sheet strength will be prioritized.
- Trilogy and SHOP occupancy expected to rise to high 80s and mid-80s, respectively, by year-end.
- Operator transitions are complete, with no further changes anticipated in the near term.
Takeaways
AHR’s Q4 2023 results confirm a strategic pivot toward high-acuity, operationally intensive senior housing, with Trilogy and SHOP driving growth and margin expansion.
- Senior Housing Is the Growth Engine: Embedded options and operational leverage in Trilogy and SHOP are set to drive future earnings accretion, with margin and occupancy gains outpacing legacy segments.
- Balance Sheet Flexibility Restored: The IPO and debt paydown give AHR capacity to pursue selective growth while maintaining leverage discipline.
- Medical Office and Triple Net Are Now Secondary: Asset sales and capital recycling will continue to shift portfolio mix toward higher-growth, needs-based care segments.
Conclusion
AHR enters its public REIT era with a clear focus on senior housing and integrated care, leveraging its Trilogy platform and SHOP rebound for growth while maintaining a conservative capital structure. The next phase will be defined by operational execution in senior housing, prudent timing of Trilogy option exercise, and disciplined capital allocation amid evolving healthcare real estate dynamics.
Industry Read-Through
AHR’s results reinforce the secular tailwind for needs-based senior housing, where demographic demand and limited new supply are driving occupancy and margin gains. Operator quality and alignment are increasingly critical, as evidenced by the impact of management transitions and the Trilogy platform’s outperformance. Medical office faces near-term headwinds from health system consolidation and shifting leasing dynamics, a theme likely to affect peers with similar exposure. REITs with operational exposure and embedded growth levers, particularly in senior care, are best positioned for the next cycle, while traditional net lease and medical office portfolios may lag without proactive asset management or capital recycling.